MBX Biosciences, Inc.
MBXNasdaq
$62.92
↑ +7.9%Jul 17 close · end-of-day
Price
1Y↑ +406.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.9B
Enterprise Value
$2.5B
P/E
—
P/S
—
P/B
6.7
EV/EBITDA
—
PEG
—
FCF Yield
-2.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$86.6M
Free Cash Flow (TTM)
-$79.8M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-19.8%
ROIC
—
Debt / Equity
—
Net Cash
$440.0M
Return 1Y
+416.0%
Company profile
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. We were founded as MBX Biosciences LLC, an Indiana limited liability company, in August 2018. We converted to a Delaware corporation in April 2019 and incorporated under the name MBX Biosciences, Inc. Our principal executive offices are located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana.
- CEO
- P. Kent Hawryluk
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Indiana
- Website
- mbxbio.com
Management & directors
- Azoulay SalomonChief Medical Officer
- Hawryluk P. KentPresident & CEO
- Bartram RichardChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
MBX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.50↓ -29.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$35.3M | -$68.2M | -$98.1M |
| Net income | -$32.6M | -$61.9M | -$87.0M |
| Diluted EPS | -$31.96 | -$5.82 | -$2.38 |
| Operating cash flow | -$32.0M | -$54.7M | -$79.9M |
| Free cash flow | -$32.1M | -$55.6M | -$81.9M |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$16.7M | -$19.6M | -$18.6M | -$26.5M | -$21.8M | -$23.9M | -$25.8M | -$27.3M |
| Net income | -$15.9M | -$18.1M | -$15.6M | -$23.9M | -$19.4M | -$21.6M | -$22.1M | -$23.5M |
| Diluted EPS | -$12.62 | -$2.78 | $19.84 | -$0.71 | -$0.58 | -$0.63 | -$0.46 | -$0.50 |
| Operating cash flow | -$13.3M | -$14.7M | -$16.0M | -$22.7M | -$17.4M | -$21.5M | -$18.3M | -$20.2M |
| Free cash flow | -$13.7M | -$14.7M | -$16.1M | -$22.7M | -$18.1M | -$21.9M | -$19.1M | -$20.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 15, 2026
Jun 12, 2026
- 38d agoMBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)investorshub.advfn.com
- 38d agoMBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidismfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-08 | Azoulay Salomon· Chief Medical Officer | Sale | 55,000 | $38.38 | $2.1M | filing |
| 2026-05-08 | Azoulay Salomon· Chief Medical Officer | Option exercise | 55,000 | $10.46 | $575,300.00 | filing |
| 2026-05-08 | Azoulay Salomon· Chief Medical Officer | Sale | 15,003 | $38.30 | $574,614.90 | filing |
| 2026-05-08 | Azoulay Salomon· Chief Medical Officer | Option exercise | 15,003 | $16.00 | $240,048.00 | filing |
| 2026-05-06 | Hawryluk P. Kent· President & CEO | Sale | 607 | $29.54 | $17,930.78 | filing |
| 2026-05-06 | Azoulay Salomon· Chief Medical Officer | Sale | 231 | $29.54 | $6,823.74 | filing |
| 2026-05-01 | Hoerter Steven L. | Award | 11,938 | $0.00 | $0.00 | filing |
| 2026-03-13 | Hawryluk P. Kent· President & CEO | Buy | 18,500 | $28.41 | $525,662.70 | filing |
| 2026-02-26 | Hawryluk P. Kent· President & CEO | Option exercise | 28,768 | $16.00 | $460,288.00 | filing |
| 2026-02-02 | Azoulay Salomon· Chief Medical Officer | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-02-02 | Bartram Richard· Chief Financial Officer | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-02-02 | Hawryluk P. Kent· President & CEO | Award | 35,250 | $0.00 | $0.00 | filing |
| 2025-10-24 | Hawryluk P. Kent· President & CEO | Option exercise | 182,859 | $3.25 | $594,291.75 | filing |
| 2025-10-20 | Hawryluk P. Kent· President & CEO | Buy | 20,000 | $13.64 | $272,790.00 | filing |
| 2025-10-17 | Hoerter Steven L. | Buy | 20,000 | $13.25 | $264,984.00 | filing |
| 2025-09-26 | Heron Patrick J | Buy | 666,666 | $18.00 | $12.0M | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.